Effect of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a meta-analysis of 10 randomized controlled trials

Jiahao Huang, Yunfei Cao, Cun Liao, Liucheng Wu, Feng Gao

Abstract

Introduction: We conducted a meta-analysis in order to investigate the effect of histamine-2-receptor antagonists (H₂RA) versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients in the intensive care unit (ICU).

Methods: A systematic literature search of Medline, EMBASE, Cochrane Central Register of Controlled Trials (1966 to January 2010) was conducted using specific search terms. A review of Web of Science and a manual review of references were also performed. Eligible studies were randomized control trials (RCTs) that compared H₂RA and sucralfate for the prevention of stress ulcer in mechanically ventilated patients. Main outcome measures were rates of overt bleeding, clinically important gastrointestinal (GI) bleeding, ventilator-associated pneumonia, gastric colonization and ICU mortality.

Results: Ten RCTs with 2,092 participants on mechanical ventilation were identified. Meta-analysis showed there was a trend toward decreased overt bleeding when H₂RA was compared with sucralfate (OR = 0.87, 95% CI: 0.49 to 1.53). A total of 12 clinically important GI bleeding events occurred among 667 patients (1.8%) in the H₂RA group compared with 26 events among 673 patients (3.9%) in the sucralfate groups. Prophylaxis with sucralfate decreased the incidence of gastric colonization (OR = 2.03, 95% CI: 1.29 to 3.19) and ventilator-associated pneumonia (OR = 1.32, 95% CI: 1.07 to 1.64). Subgroup analysis showed H₂RA was not superior to sucralfate in reducing early-onset pneumonia (OR = 0.62, 95%CI: 0.36 to 1.07) but had a higher late-onset pneumonia rate (OR = 4.36, 95%CI: 2.09 to 9.09) relative to sucralfate. No statistically significant reduction was observed in mortality of ICU between groups (OR = 1.08, 95% CI: 0.86 to 1.34).

Conclusions: In patients with mechanical ventilation, H₂RA resulted in no differential effectiveness in treating overt bleeding, but had higher rates of gastric colonization and ventilator-associated pneumonia. Additional RCTs of stress ulcer prophylaxis with H₂RA and sucralfate are needed to establish the net benefit and risks of adverse effect in mechanically ventilated patients.

Introduction

Stress-related mucosal damage might develop in the stomach and duodenum and progress to ulceration within 4 to 5 days after injury. Intensive care unit (ICU) patients are prone to develop stress-related gastrointestinal (GI) hemorrhage, which is associated with increased morbidity and mortality. Respiratory failure, hypotension, and coagulopathy are the strongest risk factors for clinically important GI bleeding [1-4], especially for those patients with prolonged mechanical ventilation, who have a 4- to 21-fold risk of stress ulceration compared with those patients without prolonged mechanical ventilation [5,6]. Therefore, prophylaxis against stress ulceration traditionally has been recommended for the prevention of upper
GI hemorrhage in critically ill patients. Antacids, which are the first agents employed to significantly decrease the incidence of stress ulcer, have been widely displaced by histamine-2-receptor antagonists (H2RAs) and sucralfate because of the excessive nursing-time demand that results from frequent dosing and gastric pH testing. H2RA, such as ranitidine and cimetidine, blocks the secretion of gastric acid and raises the gastric pH, promoting the proliferation of bacteria - particularly, Gram-negative bacilli, tracheobronchial colonization, and nosocomial pneumonia - in the stomach [7-9]. Sucralfate, which does not alter gastric pH, exerts its topical effect on ulcer disease by binding to the proteins of the ulcer site. Cook and colleagues [10] found, in contrast, that universal prophylaxis may not be warranted as only 1 patient out of 1,000 treated would benefit from the prophylaxis. Saint and Matthay [11] considered that stress ulceration prophylaxis never demonstrated a benefit in decreasing the incidence of mortality.

To our knowledge, no previous systematic review in stress ulcer prophylaxis has definitively established whether H2RA and sucralfate decrease clinically important GI bleeding, nor has any study generated clinical recommendations of different prophylactic regimens. Cook and colleagues [12] conducted a meta-analysis of the effect of stress ulcer prophylaxis and identified a trend toward a decreased incidence of nosocomial pneumonia when sucralfate was compared with H2RA. Moreover, a recent meta-analysis [13] reported a significantly increased risk of pneumonia with ranitidine compared with sucralfate. The study, however, was limited by small sample size (in particular, of patients with pneumonia) and therefore might not be reliable. In addition, the end point of ‘clinically important GI bleeding’ was not homogeneous in the trials included in the study [12]. To reconcile the inconsistencies in the prior studies, we attempted to summarize the available randomized controlled trials (RCTs) and gain adequate sample size and power by combining the results of several studies in a rigorous scientific overview that compared H2RA and sucralfate. We attempted to ascertain the frequencies of overt bleeding, clinically important GI bleeding, occurrence of ventilator-associated pneumonia (VAP), gastric colonization, and ICU mortality in a large series of mechanically ventilated patients in the ICU.

Materials and methods

Data sources

A comprehensive search was performed to identify RCTs in Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science in any language between 1966 and January 2010. The following search terms, alone or in combination, were used: stress ulcer, histamine-2-receptor antagonists, ranitidine, cimetidine, famotidine, sucralfate, mechanical ventilation, and randomized controlled trials. No language restrictions were imposed. An independent search using Web of Science was conducted to ensure that all relevant clinical trials were included in the meta-analysis. In addition, bibliographies of retrieved articles were manually searched for other relevant studies.

Study selection

Clinical trials that met the following criteria were included in the meta-analysis: (a) randomized trials of an H2RA (including ranitidine, cimetidine, and famotidine) compared with sucralfate, (b) trials with adults who were projected to require mechanical ventilation for at least 48 hours in the ICU, and (c) trials with available data on the proportion of patients with overt bleeding, clinically important GI bleeding, and VAP or with gastric colonization and ICU mortality. Applying these prespecified inclusion criteria, two investigators independently reviewed all potentially relevant articles, and disagreement among investigators was resolved by consensus. When two studies had substantial overlap in terms of investigator, institution, and study population, the one that was more recent and of better quality was included.

Quality assessment

Two reviewers independently evaluated each study while using a critical review checklist of the Dutch Cochrane Centre [14]. The following methodological features most relevant to the control of bias were assessed: adequate sequence generation, allocation concealment, blinding, selective outcome reporting, and other sources of bias. Each criterion was categorized as ‘yes’, ‘no’, or ‘unclear’, and the summary assessments of the risk of bias for each important outcome within and across studies were categorized as ‘low risk of bias’, ‘unclear risk of bias’, or ‘high risk of bias’.

Data extraction

Two independent reviewers abstracted the data in a traditionalized format. The following information was sought from each article: first author identification, year of publication, country, study duration, sample size, duration of patient follow-up, participant characteristics (patient number and mean age), Acute Physiology and Chronic Health Evaluation II (APACHE II) score (range of scores was 0 to 71, with higher scores indicating a more severe illness) [15], and intervention (drug and dose). Discrepancies in data extraction were to be resolved by consensus, referring back to the original article, and by contacting the study authors if necessary.
The primary end points of the meta-analysis were overt bleeding, clinically important GI bleeding, and VAP in the population of patients who received H2RA therapy in comparison with those who received sucralfate. Secondary end points were gastric colonization and ICU mortality.

In this study, overt bleeding was defined as signs of hematemesis, naso gastric aspirate containing blood or coffee-ground material, melena, or hematochezia, the last of which was a potential problem in the mechanically ventilated patients as a result of stress ulceration. Clinically important GI bleeding was defined as overt bleeding accompanied by at least one of the following: (a) a decrease in blood pressure of 20 mm Hg within 24 hours of bleeding, (b) a decrease in blood pressure of 10 mm Hg and an increase in heart rate of 20 beats per minute on orthostatic change after upper GI bleeding, or (c) a decrease in hemoglobin of 20 g/L and transfusion of 2 units of blood within 24 hours or gastric bleeding requiring surgery. We included the studies that precisely met the definition of ‘ventilator-associated pneumonia’ according to Cook and colleagues [16]. The early-onset and late-onset pneumonias were diagnosed if they occurred during the first 4 days before or 4 days after the initiation of mechanical ventilation, respectively. Consequently, only patients observed for more than 4 days could be evaluated for the development of late-onset pneumonia. A patient was considered to have gastric colonization with high counts when quantitative culture of at least one specimen had more than 100 colony-forming units/mL, and ICU mortality was considered to occur as death from any cause between the date of random assignment and the end of the active study phase in the ICU.

Data synthesis

Version 9.2 of the Stata program (StataCorp LP, College Station, TX, USA) was used for statistical analysis. Data were analyzed by an intention-to-treat analysis, so all patients who were randomly allocated to one treatment arm or the other were analyzed together regardless of whether they completed, or indeed received, regimens. To standardize reporting of our results, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated from raw data of every trial. For the meta-analysis, we initially used the fixed-effects model [17], based on inverse variance weights for combined results from the individual trials. The Cochran $\chi^2$ and the $I^2$ statistic were first calculated to assess the heterogeneity among the proportions of the included trials. If the $P$ value was less than 0.1 and $I^2$ was greater than 50%, the assumption of homogeneity was deemed invalid, and the following techniques were employed to explore the heterogeneity: (a) subgroup analysis, (b) sensitivity analysis performed by omitting one study in each turn and investigating the influence of a single study on the overall meta-analysis estimate when necessary, and (c) if the heterogeneity still existed, randomized-effects models as described by DerSimonian and Laird [18] were applied to incorporate between-study heterogeneity in addition to sampling variation for the calculation of summary OR estimates and corresponding 95% CIs. Otherwise, the pooled event rate data for each treatment group were presented alongside the common OR results obtained from the pooled analysis in the fixed-effects model. The Egger regression test, Begg adjusted rank correlation test, and visual inspection of a funnel plot were performed to assess publication bias [19,20]. A two-tailed $P$ value of less than 0.05 was considered statistically significant. Circumstances that might bring about clinical heterogeneity included differences in severity of disease, intervention dosage, measurements, and management. This work was performed in accordance with the Quality of Reporting of Meta-analyses (QUOROM) guidelines for meta-analysis of randomized clinical trials [21].

Results

Study characteristics

The search strategy generated 912 references: Medline ($n = 304$), Embase ($n = 565$), and CENTRAL ($n = 43$). A total of 77 potentially eligible studies were identified by literature search. We excluded 62 studies in which participants did not receive mechanical ventilation in the ICU. Three studies were excluded because they failed to report adequate data, one was based on pediatric population, and one paper did not have comparable therapy groups. Finally, 10 remaining trials [16,22-30] were determined to have met the inclusion criteria and were invited to collaborate. The flowchart of the literature search of this meta-analysis is shown in Figure 1. Eight trials tested ranitidine therapy versus sucralfate, and one trial examined famotidine versus sucralfate. Of the 2,092 participants, 1,041 were randomly assigned to H2RA (970 received ranitidine and 71 received famotidine) and 1,051 were randomly assigned to sucralfate. Details of the included studies are summarized in Table 1. Patient enrollment ranged from 16 to 604, mean age of patients ranged from 26.8 to 60.0 years, and the duration of follow-up ranged from 7 to 27.3 days. Ranitidine doses ranged from 150 to 300 mg/day, and sucralfate doses ranged from 4 to 6 g/day. Participants included ICU patients, who required mechanical ventilation for more than 2 days. Patients’ baseline characteristics in treatment groups were well balanced according to APACHE II score.
Quality assessment of the trials

Treatment assignments were the typical method of ‘randomization’ across studies in this meta-analysis. Randomized treatment allocation sequences were generated in six trials [16,22,23,25-27]; for the other four trials [24,28-30], the method reported was judged to be unclear on the basis of the available documents. The original papers clearly stated that blinding was conducted across the studies and therefore the outcome measurements were not likely to be influenced by lack of blinding. The numbers and reasons for withdrawal/dropout were reported in detail across trials. None of the trials had extreme imbalances at baseline or was stopped early. Thus, the trials were free of other sources of bias. Therefore, six studies [16,22,23,25-27] were categorized as low risk of bias (plausible bias unlikely to seriously alter the results), and the other four studies [24,28-30] were categorized as unclear risk of bias (plausible bias that raises some doubt about the results). An overview of the quality appraisal is shown in Table 2.

Overt bleeding

Six RCTs [22,24-26,28,29] compared the incidence of overt bleeding with H2RA and sucralfate. A total of 24 overt-bleeding events occurred among 314 patients (7.6%) in the H2RA group compared with 28 events among 323 patients (8.7%) in the sucralfate group. Compared with sucralfate therapy, H2RA therapy was not associated with a significant reduction in the risk of overt bleeding, and no heterogeneity was detected across trials (OR 0.87, 95% CI 0.49 to 1.53, \( P = 0.623 \), \( I^2 = 0.0 \% \); Figure 2).

Clinically important gastrointestinal bleeding

The events of clinically important GI bleeding were explored in three studies [16,23,30]. The pooled analysis of the clinically important GI-bleeding rate for H2RA versus sucralfate showed a significant heterogeneity (\( P = 0.074 \), \( I^2 = 61.7 \% \)). On the basis of the results of the sensitivity analysis, one study [30] was excluded. The subsequent analysis was based on two trials [16,23], and a total of 12 clinically important GI-bleeding events occurred among 667 patients (1.8%) in the H2RA group compared with 26 events among 673 patients (3.9%) in the sucralfate group. Nevertheless, the sample sizes were highly variable across trials, one of which contained more than nine times as many subjects as the others. Therefore, it was inappropriate to pool the data.

Ventilator-associated pneumonia

VAP data required for meta-analysis was available from eight studies [16,22,23,25-27,29,30]. The incidence of VAP in the H2RA group was 243/998 (24.4%) and that of the sucralfate group was 199/1,006 (19.8%). Pooled analysis of OR showed that VAP was significantly less prominent among participants receiving sucralfate in relation to H2RA, and the results were robust and there was no evidence of heterogeneity (OR 1.32, 95% CI 1.07 to 1.64, \( P = 0.011 \), \( P \) of heterogeneity = 0.236, \( I^2 = 24.2 \% \); Figure 3).

Subgroup analyses

Three trials [22,25,26] that included a total of 373 patients (H2RA, \( n = 185 \); sucralfate, \( n = 188 \)) provided data to allow us to conduct subgroup analyses based on early- or late-onset pneumonia. A total of 28 early-onset pneumonia events occurred among 185 patients (15.1%) receiving H2RA therapy compared with 41 events among 188 patients (21.8%) receiving sucralfate therapy, and we found no significant difference according to the incidence rates of early-onset pneumonia (OR 0.62, 95% CI 0.36 to 1.07, \( P = 0.085 \)). Only for the outcome of late-onset pneumonia did we find a significant difference suggesting higher frequencies of late-onset pneumonia with the patients receiving H2RA compared with those receiving sucralfate (H2RA: 36/185 [19.5%]; sucralfate: 10/188 [5.3%]; OR 4.36, 95% CI 2.09 to 9.09, \( P < 0.001 \)). No heterogeneity was detected in those two subgroup analyses, and \( P \) values were 0.362 and 0.725, respectively.

Gastric colonization

Four studies assessing 413 participants who were randomly assigned to receive H2RA therapy (\( n = 206 \)) or sucralfate therapy (\( n = 207 \)) provided the information on gastric colonization [22,23,26,29]. Pooled analysis of OR showed that there was a significant difference of
| Study                          | Country      | Study design | Duration       | Follow-up                    | Treatment groups | APACHE II score | Patients | Intervention                                      |
|-------------------------------|--------------|--------------|----------------|------------------------------|------------------|-----------------|----------|--------------------------------------------------|
| Prakash et al. [22], 2008     | India        | RCTs         | _              | 7 days                       | Ranitidine       | 14.21 ± 5.44    | 25       | Ranitidine 50 mg IV, every 6 hours                |
|                               |              |              |                |                              | Sucralfate       | 13.34 ± 6.03    | 25       | Sucralfate 1 g IV, every 6 hours                  |
| Kantorova et al. [23], 2004   | Czech Republic | RCTs         | Feb. 2000-June 2002 | Until discharge or death | Famotidine       | 19.1 ± 9.3      | 71       | Famotidine 40 mg IV, every 12 hours               |
|                               |              |              |                |                              | Sucralfate       | 18.8 ± 8.1      | 69       | Sucralfate 1 g IV, every 6 hours                  |
| Darlong et al. [24], 2003     | India        | RCTs         | _              | _                            | Ranitidine       | _               | 24       | Ranitidine 50 mg IV, every 8 hours                |
|                               |              |              |                |                              | Sucralfate       | 21              | 39.5     | Sucralfate 1 g IV, every 8 hours                  |
| Cook et al. [16], 1998        | Canada       | Multicenter RCTs | Oct. 1992-May 1996 | Until discharge or death | Ranitidine       | 24.7 ± 7.1      | 596      | Ranitidine 50 mg IV, every 8 hours                |
|                               |              |              |                |                              | Sucralfate       | 24.6 ± 7.3      | 604      | Sucralfate 1 g IV, every 6 hours                  |
| Thomason et al. [25], 1996    | USA          | RCTs         | Nov. 1990-May 1994 | 27.3 days                  | Ranitidine       | 17.0 ± 136      | 31.0     | Ranitidine 150 mg/day, continuous IV             |
| Prod’hom et al. [26], 1994    | Switzerland  | RCTs         | Jan. 1989-Jan. 1991 | _                          | Ranitidine       | 16.8 ± 86       | 80       | Ranitidine 150 mg/day, continuous IV             |
|                               |              |              |                |                              | Sucralfate       | 17.2 ± 86       | 83       | Sucralfate 1 g IV, every 4 hours                  |
| Pickworth et al. [27], 1993   | USA          | RCTs         | Jan. 1989-Aug. 1991 | Until discharge or death | Ranitidine       | 18.1 ± 6.5      | 44       | Ranitidine 50 mg IV, every 6 hours                |
|                               |              |              |                |                              | Sucralfate       | _               | 26.8     | Sucralfate 1 g IV, every 6 hours                  |
| Ruiz-Santana et al. [28], 1991| Spain        | RCTs         | Dec. 1998-Jan. 1990 | Until discharge or death | Ranitidine       | 15 ± 5          | 19       | Ranitidine 50 mg IV, every 6 hours                |
|                               |              |              |                |                              | Sucralfate       | 24              | 390 ± 17  | 14/5                                             |
| Eddleston et al. [29], 1991   | UK           | RCTs         | _              | _                            | Ranitidine       | 12.4 ± 1.5      | 30       | Ranitidine 50 mg IV, every 6 hours                |
|                               |              |              |                |                              | Sucralfate       | 11.6 ± 1.3      | 30       | Sucralfate 1 g IV, every 6 hours                  |
| Laggner et al. [30], 1989     | Austria      | RCTs         | _              | Until discharge or death     | Ranitidine       | _               | 16       | Ranitidine 50 mg IV, every 4 hours               |
|                               |              |              |                |                              | Sucralfate       | _               | 47 ± 19   | 11/5                                             |

The range of Acute Physiology and Chronic Health Evaluation II (APACHE II) scores was 0 to 71, with higher scores indicating a more severe illness. *If pH was less than 3.5, ranitidine 100 mg IV, intravenous (injection); RCT, randomized controlled trial.
gastric colonization between the two groups (OR 2.72, 95% CI 1.80 to 4.13), with heterogeneity among the trials (P of heterogeneity was less than 0.001). Sensitivity analysis indicated that the outcome was not robust until we excluded the study by Prakash and colleagues [22], and so the source of heterogeneity could be mainly from that trial. The heterogeneity disappeared after the removal of that study, and the remaining trials showed that there was a significant difference in gastric colonization between H2RA and sucralfate (OR 2.03, 95% CI 1.29 to 3.19, P = 0.002, P of heterogeneity = 0.298, I2 = 17.5%).

Intensive care unit mortality
The ICU mortality rate during the active study period for participants who were treated with H2RA was 204/1,001 and that of participants treated with sucralfate was 196/1,014, according to eight trials with available data [16,22,23,25-29]. Compared with the OR of mortality associated with sucralfate, the OR of mortality associated with H2RA was 1.08 (95% CI 0.86 to 1.34, P = 0.514), indicating that the result was not statistically significant comparing H2RA with sucralfate in reducing overall ICU mortality. No heterogeneity across trials was detected by the χ² test, and the P value was 0.537 (I² = 0.0%; Figure 4).

Publication bias
Inspection of funnel plots and statistical tests for publication bias did not show an obvious effect of publication bias (Egger test, P = 0.208; Begg test, P = 0.536; Figure 5).

Discussion
The potential differences among the prophylactic regimens of critically ill patients have evoked great interest from clinicians, scientists, and the public. During the past few decades, studies and overviews have investigated this topic, but consistent results have not been reported and no individual study has definitively established whether these agents decrease clinically important GI bleeding. The meta-analysis [13] suggested that ranitidine and sucralfate do not prevent GI bleeding in ICU patients. In contrast, the overview of Pérez and

Table 2 Quality assessment of studies included in the meta-analysis

| Study                  | Adequate sequence generation | Allocation concealment | Blinding | Incomplete outcome data addressed | Selective outcome reporting | Free of other bias | Summary risk of bias |
|------------------------|------------------------------|------------------------|----------|----------------------------------|----------------------------|-------------------|----------------------|
| Prakash et al. [22], 2008 | Yes                          | Yes                    | Yes      | Yes                              | Yes                        | Yes               | Low                  |
| Kantorova et al. [23], 2004 | Yes                          | Yes                    | Yes      | Yes                              | Yes                        | Yes               | Low                  |
| Darlong et al. [24], 2003 | Yes                          | Unclear                | Unclear  | Yes                              | Yes                        | Yes               | Unclear              |
| Cook et al. [16], 1998  | Yes                          | Yes                    | Yes      | Yes                              | Yes                        | Yes               | Low                  |
| Thomason et al. [25], 1996 | Yes                          | Yes                    | Yes      | Yes                              | Yes                        | Yes               | Low                  |
| Prod’homme et al. [26], 1994 | Yes                          | Yes                    | Yes      | Yes                              | Yes                        | Yes               | Low                  |
| Pickworth et al. [27], 1993 | Yes                          | Yes                    | Yes      | Yes                              | Yes                        | Yes               | Low                  |
| Ruiz-Santana et al. [28], 1991 | Yes                          | Unclear                | Yes      | Yes                              | Yes                        | Yes               | Unclear              |
| Eddleston et al. [29], 1991 | Yes                          | Unclear                | Yes      | Yes                              | Yes                        | Yes               | Unclear              |
| Laggner et al. [30], 1989 | Yes                          | Unclear                | Yes      | Yes                              | Yes                        | Yes               | Unclear              |

Figure 2 Overt bleeding of histamine-2-receptor antagonists (H2RA) versus sucralfate. Fixed-effects model of odds ratio (95% confidence interval, or CI) of overt bleeding associated with H2RA compared with sucralfate is shown.
Dellinger [31] in 2001 still strongly recommended stress ulcer prophylaxis, particularly in patients with mechanical ventilation, hypotension, and coagulopathy. Moreover, although recognizing the duration of intubation was an important risk factor for the development of VAP, no meta-analysis comparing stress ulcer prophylaxis had analyzed when the pneumonic episodes had developed in the study participants. It was extremely important that VAP developing early or late after intubation might differ in the bacterial species that were recovered from the trachea [32-34] and that therefore were likely to be related to different pathophysiologic mechanisms.

We therefore included recently published studies and generated a meta-analysis to elucidate and quantitatively assess the differences in the effect of H2RA versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients in the ICU. The present study, in which we identified and evaluated 10 relevant RCTs comparing H2RA therapy versus sucralfate therapy, was based on individual patient data from 2,092 patients enrolled in RCTs conducted by independent investigators. Results of this meta-analysis demonstrated that, for patients with mechanical ventilation, a comparable incidence of overt bleeding was associated with H2RA in comparison with sucralfate. From our analysis, with all available articles, we confirmed the finding of single trials that sucralfate was associated with significantly lower rates of incidence of gastric colonization, VAP, and late-onset pneumonia relative to H2RA. The analysis demonstrated that equivalent incidence rates were observed between the two groups with regard to early-onset pneumonia and ICU mortality rate.

Results concerning gastric-bleeding prevention were consistent with the prior meta-analysis [12] and were replicated in the current analysis as we found no evidence that H2RA and sucralfate differ with respect to the prevention of overt bleeding. First, the reason for replication was that the two included trials of greatest weight also fulfilled Cook and colleagues’ criterion of overt bleeding [12]. Second, the analysis of data was based on similar definitions of overt bleeding. Third, both of them used the fixed-effects model for the analytic strategy.

The present study showed a marked reduction in clinically important GI bleeding with H2RA (1.8%) in relation to sucralfate (3.9%). Nevertheless, it was inappropriate to pool the data given that the sample sizes were highly variable across trials, one of which contained more than nine times as many subjects as the other. There were several discrepancies between our study and the previous studies. First, the analysis of different data was based on different definitions of clinically important GI bleeding. Second, the participants who developed clinically important GI bleeding were not homogeneous in the included trials of study, which did not fulfill the ‘clinically important GI bleeding’ criterion that the trials themselves established [12]. In our study, we rigorously abstracted data from original studies published online, but we did not modify the data. In addition, combined and included studies definitely met the criterion of ‘clinically important GI bleeding’ as defined above in the ‘Data extraction’ section. In the present study, a definitive conclusion that critically ill patients undergoing mechanical ventilation ought to receive prophylaxis with H2RA or sucralfate to prevent clinically important GI bleeding could not be established.

With respect to VAP, a recent meta-analysis [13] suggested that sucralfate was associated with decreased incidence rates of VAP in comparison with H2RA, whereas another study [12] found only a trend toward a decreased incidence of VAP when sucralfate was compared with H2RA, but the trend was not statistically significant. The finding of our meta-analysis indicated that incidence rates of VAP were significantly more prominent in the H2RA group than in the sucralfate group (OR 1.32, 95% CI 1.07 to 1.64). Although no statistically significant difference in the incidence rates of early-onset pneumonia was found between groups, patients on H2RA were associated with an increased incidence of late-onset pneumonia (OR 4.36, 95% CI 2.09 to 9.09). In addition, patients receiving H2RA had higher magnitudes of gastric colonization than did patients receiving sucralfate (OR 2.03, 95% CI 1.29 to 3.19). Importantly, in spite of evidence of heterogeneity among trials, the heterogeneity would be expected as a result of chance;
this was not surprising given the certain differences in target populations and methods. We postulated that the lower incidence of late-onset pneumonia in the sucralfate group appeared to be associated mainly with the fact that sucralfate did not alter the gastric pH, for the gastric pH has been shown to greatly affect the bacterial colonization of the stomach [35-37]. Thus, patients receiving this drug were able to maintain a low gastric pH and suppress bacterial growth. In that case, in early-onset pneumonia that developed during the first few days after intubation, the spectrum of bacteria (which mostly included oropharyngeal species) were probably considered to have been introduced in the trachea before or at the time of intubation.

All available trials were aggregated to evaluate the effect of H2RA and sucralfate on ICU mortality. In

Figure 4 Intensive care unit mortality of histamine-2-receptor antagonists (H2RA) versus sucralfate. Fixed-effects model of odds ratio (95% confidence interval, or CI) of intensive care unit mortality associated with H2RA compared with sucralfate is shown.

Figure 5 Publication bias of the meta-analysis. Publication bias for the outcome of ventila-tor-associated pneumonia in studies of the effects of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients is shown. s.e., standard error.

studies evaluating mortality, we observed similar rates of ICU mortality among patients receiving H2RA (204 of 1,001 [20.4%]) and those receiving sucralfate (196 of 1,014 [19.3%]), and there was no significant difference between groups (OR 1.08, 95% CI 0.86 to 1.34). Other investigators reported that development of VAP might lead to an additional 13 days in the ICU [38]. Although the frequencies of VAP were less prominent among participants receiving sucralfate in relation to H2RA, the effect of this type of pneumonia appeared to have no direct relation with mortality. More high-quality RCTs were needed to explore the associated factors of mortality in the ICUs.

To our knowledge, our study was the first attempt to summarize the available data on the comparison of H2RA and sucralfate effects on stress ulcer prophylaxis in mechanically ventilated patients in the ICU. There were several novel aspects in our study: early- and late-onset pneumonias were first evaluated through subgroup analysis, allowing the combination of comparable estimates. Furthermore, an advantage of our analysis was that the definitions of outcome measures were clearly defined in the present study and this resulted in precise results.

However, we do acknowledge that there are several limitations of the present study. First, the geographic regions covered in this meta-analysis include North America (the US and Canada) [16,25,27], Europe (the Czech Republic, Switzerland, Austria, and Spain) [23,26,28,30], and Asia (India) [22-24]. Therefore, our results have limited generalizability to other regions (for example, Africa and Latin America). Second, a small number of studies and participants in particular outcome measures were available. Although lower frequencies of clinically important GI bleeding were noted in the H2RA group (12/667 [1.8%]) compared with the sucralfate group (26/673 [3.9%]), the result would have been attributed to the definitive RCT published by Cook and colleagues [16] if the data of the two trials had been synthesized, and this probably limited the detection of the effect estimate. Therefore, it was inappropriate to pool the data. Finally, differences in APACHE II score and intervention dosage might have affected the outcome of patients' response to medical management and might have produced possible clinical heterogeneity.

Conclusions

This meta-analysis demonstrated that, compared with sucralfate for the prevention of stress ulcer in mechanically ventilated patients, H2RA showed no differential effectiveness in treating overt bleeding but had the disadvantages of higher gastric colonization and VAP rates. In clinical practice, the increased risks of adverse effect had to be balanced against the benefits of treatment.
with H2RA while taking into account each patient’s clinical circumstances. Larger prospective RCTs and additional African and Latin American studies of H2RA and sucralfate are warranted among patients with mechanical ventilation in order to allow firm conclusions to be drawn about clinical benefit and risks, particularly clinically important GI bleeding.

Key messages
- The literature shows that histamine-2-receptor antagonists (H2RA) result in no differential effectiveness in treating overt bleeding but have higher rates of gastric colonization and ventilator-associated pneumonia on stress ulcer prophylaxis in mechanically ventilated patients in the intensive care unit.
- There is a lack of consensus in the literature in regard to the effect of H2RA versus sucralfate in treating clinically important gastrointestinal bleeding.
- Larger prospective randomized controlled trials and additional African and Latin American studies of H2RA and sucralfate are warranted and may have a positive impact on overall estimates.

Abbreviations
- APACHE II: Acute Physiology and Chronic Health Evaluation II; CENTRAL: Cochrane Central Register of Controlled Trials; CI: confidence interval; GI: gastrointestinal; H2RA: histamine-2-receptor antagonists; ICU: intensive care unit; OR: odds ratio; RCT: randomized controlled trial; VAP: ventilator-associated pneumonia.

Acknowledgements
This meta-analysis was funded by the Department of Colorectal and Anal Surgery of the First Affiliated Hospital of Guangxi Medical University (Nanning, Guangxi, People’s Republic of China).

Authors’ contributions
FG and YC conceived the study and helped with manuscript revisions. CL and additional African and Latin American studies of H2RA and sucralfate are warranted and may have a positive impact on overall estimates.

Competing interests
The authors declare that they have no competing interests.

Received: 23 August 2010 Revised: 13 October 2010 Accepted: 29 October 2010 Published: 29 October 2010

References
1. Kamada T, Fusamoto H, Kawano S, Noguchi M, Hiramatsu K: Gastrointestinal bleeding following head injury: a clinical study of 433 cases. J Trauma 1977, 17:44-47.
2. Schuster DP, Rowley H, Feinstein S, McCue MK, Zuckerman GR: Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit. Am J Med 1984, 76:623-630.
3. Lacroix J, Nadeau D, Laberge S, Gauthier M, Lapiere G, Farrell CA: Frequency of upper gastrointestinal bleeding in a pediatric intensive care unit. Crit Care Med 1992, 20:35-42.
4. Cook DJ, Laine LA, Guyatt GH, Raffin TA: Nosocomial pneumonia and the role of gastric pH. A meta-analysis. Chest 1991, 100:7-13.
5. Ben-Menachem T, McCarthy BD, Fogel R, Schiffman RM, Patel RV, Zarowitz BJ, Nerenz DR, Resiser RS: Prophylaxis for stress-related gastrointestinal hemorrhage: a cost effectiveness analysis. Crit Care Med 1996, 24:338-345.
6. Borrero E, Bank S, Mangolis I, Schulman ND, Chardavoine R: Comparison of antacid and sucralfate in the prevention of gastrointestinal bleeding in patients who are critically ill. Am J Med 1983, 75:62-64.
7. Atherton ST, White DJ: Stomach as source of bacteria colonising respiratory tract during artificial ventilation. Lancet 1978, 2:969-970.
8. du Moulin GC, Paterson DG, Hedley-Whyte J, Lisbon A: Aspiration of gastric bacteria in antacid-treated patients: a frequent cause of postoperative colonisation of the airway. Lancet 1982, 1242-245.
9. Craven DE, Kuchens LM, Klinisky V, Lichtenberg DA, Make BJ, McCabe WR: Risk factors for pneumonia and mortality in patients receiving continuous mechanical ventilation. Am Rev Respir Dis 1986, 133:392-396.
10. Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, Winton TL, Rutledge F, Todd T, Roy P, Lacroix J, Griffith L, Willan A: Risk factors for gastrointestinal bleeding in critically ill patients Canadian Critical Care Trials Group. N Engl J Med 1994, 330:577-581.
11. Saint S, Matthay MA: Risk reduction in the intensive care unit. Am J Med 1998, 105:515-523.
12. Cook DJ, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Buckingham L, Tryba M: Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA 1996, 275:308-314.
13. Messoni A, Trippoli S, Vaiani M, Gorini M, Corrado A: Bleeding and pneumonia in intensive care patients given ranitidine and sucralfate for prevention of stress ulcer: meta-analysis of randomised controlled trials. BMJ 2000, 321:1103-1106.
14. Higgins JPT, Green S (Eds): Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.1 [updated September 2008]. Oxford, UK: The Cochrane Collaboration, 2008.
15. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
16. Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, Peters S, Rutledge F, Griffith L, McClean A, Wood G, Kirby A: A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 1998, 338:791-797.
17. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F: Methods for Meta-analysis in Medical Research. Chichester, UK: John Wiley & Sons Ltd, 2000.
18. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
19. Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
20. Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
21. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF: Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999, 354:1896-1900.
22. Prakash S, Rai A, Goggia AR, Prakash S: Nosocomial pneumonia in mechanically ventilated patients receiving ranitidine or sucralfate as stress ulcer prophylaxis. Indian Journal of Anaesthesia 2008, 52:179-184.
23. Kantorova I, Svoboda P, Scheer P, Doubek J, Rehorikova D, Bosiakova H, Ochmann J: Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology 2004, 51:757-761.
24. Darlong V, Jayakshomi TS, Kaul HL, Tandon R: Stress ulcer prophylaxis in patients on ventilator. Trop Gastroenterol 2003, 24:124-128.
25. Thomason MH, Payseur ES, Hakenewerth AM, Norton HJ, Mehta B, Reeves TR, Moore-Swartz MW, Robbins P: Nosocomial pneumonia in ventilated trauma patients during stress ulcer prophylaxis with sucralfate, antacid, and ranitidine. J Trauma 1996, 41:503-508.
26. Prodhorn G, Leuenberger P, Kuefer J, Blum A, Chioleco R, Schaller MD, Perret C, Spinnler G, Blondel J, Siegrist H, Saghafi L, Blanc D, Franceschi P: Nosocomial pneumonia in mechanically ventilated patients receiving antacid, ranitidine, or sucralfate as prophylaxis for stress ulcer. A randomized controlled trial. Ann Intern Med 1994, 120:653-662.
27. Pickworth KK, Falcone RE, Hoogeboom JE, Santanello SA: Occurrence of nosocomial pneumonia in mechanically ventilated trauma patients: a comparison of sucralfate and ranitidine. Crit Care Med 1993, 21:1856-1862.
28. Ruiz-Santana S, Ortiz E, Gonzalez B, Bolanos J, Ruiz-Santana AJ, Manzano JL: Stress-induced gastrointestinal lesions and total parenteral nutrition in critically ill patients: frequency, complications, and the value of prophylactic treatment. A prospective, randomized study. Crit Care Med 1991, 19:867-871.
29. Eddleston JM, Vohra A, Scott P, Tooth JA, Pearson RC, McCloy RF, Morton AK, Doran BH: A comparison of the frequency of stress ulceration and secondary pneumonia in sucralfate- or ranitidine-treated intensive care unit patients. Crit Care Med 1991, 19:1491-1496.

30. Laggner AN, Lenz K, Baue W, Druml W, Schneeeweiß B, Grimm G: Prevention of upper gastrointestinal bleeding in long-term ventilated patients. Sucralfate versus ranitidine. Am J Med 1989, 86:81-84.

31. Pérez J, Dellinger RP, International Sepsis Forum. Other supportive therapies in sepsis. Intensive Care Med 2001, 27(Suppl 1):S116-S127.

32. Langer M, Cigada M, Mandelli M, Mosconi P, Tognoni G. Early onset pneumonia: a multicenter study in intensive care units. Intensive Care Med 1987, 13:342-346.

33. Lowy FD, Carlisle PS, Adams A, Feiner C. The incidence of nosocomial pneumonia following urgent endotracheal intubation. Infect Control 1987, 8:245-248.

34. Pugin J, Auckenthaler R, Lew DP, Suter PM. Oropharyngeal decontamination decreases incidence of ventilator-associated pneumonia. A randomized, placebo-controlled, double-blind clinical trial. JAMA 1991, 265:2704-2710.

35. Delks MR, Craven DE, Celli BR, Manning M, Burke RA, Garvin GM, Kunches LM, Farber HW, Wedel SA, McCabe WR. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med 1987, 317:1376-1382.

36. Donowitz LG, Page MC, Mileur BL, Guenther SH. Alteration of normal gastric flora in critical care patients receiving antacid and cimetidine therapy. Infect Control 1987, 7:23-26.

37. Forster A, Neethamre T, Suter P, Pitteloud JJ, Intarte F, Ducel G, Morel D. Influence of cimetidine on bacterial growth in gastric fluid. Nouv Presse Med 1982, 11:2281-2283.

38. Fagon JY, Chastre J, Domart Y, Trouillet JL, Pierre J, Darte C, Gibert C. Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989, 139:877-884.

doi:10.1186/cc9312

Cite this article as: Huang et al. Effect of histamine-2-receptor antagonists versus sucralfate on stress ulcer prophylaxis in mechanically ventilated patients: a meta-analysis of 10 randomized controlled trials. Critical Care 2010 14:R194.